Cytomegalovirus in liver transplant recipients: there are many ways to Rome.
Rayes
Nada
N
Seehofer
Daniel
D
Neuhaus
Peter
P
D000998:Antiviral Agents / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000821:virology; D006085:Graft Survival; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D017093:Liver Failure / Q000175:diagnosis / Q000401:mortality / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000401:mortality; D008297:Male; D009894:Opportunistic Infections / Q000517:prevention & control* / Q000821:virology; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications / Q000453:epidemiology / Q000821:virology; D011322:Primary Prevention / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D015996:Survival Rate; D014181:Transplantation Immunology
D000998:Antiviral Agents; D004279:DNA, Viral